Nuvation Bio
NUVB
99 hedge funds and large institutions have $1.36B invested in Nuvation Bio in 2021 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 23 closing their positions.
113% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 23
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
36% more funds holding
Funds holding: 73 → 99 (+26)
0.81% more ownership
Funds ownership: 67.19% → 68% (+0.81%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less capital invested
Capital invested by funds: $1.48B → $1.36B (-$113M)
100% less call options, than puts
Call options by funds: $6K | Put options by funds: $1.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.2M |
| 2 |
BlackRock
New York
|
+$20.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10M |
| 4 |
DM
Deerfield Management
New York
|
+$6.58M |
| 5 |
Renaissance Technologies
New York
|
+$5.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14.4M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$11M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$10.4M |
| 4 |
O
OrbiMed
New York
|
-$8.36M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.22M |
NUVB Hedge Fund Activity: Q2 2021 in Review
99 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q2 2021, worth a combined $1.36B — down 7.7% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new NUVB positions and 23 closed out — a net gain of 26 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Vanguard Group, adding an estimated $47.2M. The largest seller was Millennium Management, exiting entirely with an estimated $14.4M sold.
- 99 institutional investors held Nuvation Bio (NUVB) as of Q2 2021, up from 73 in Q1 2021.
- Funds reported $1.36B of Nuvation Bio stock for Q2 2021, down 7.7% quarter-over-quarter.
- 49 funds opened new Nuvation Bio positions in Q2 2021 and 23 closed out, a net change of +26 holders.
- The largest Nuvation Bio buyer in Q2 2021 was Vanguard Group, an estimated $47.2M added.
- The largest Nuvation Bio seller in Q2 2021 was Millennium Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2021.